Pegfilgrastim with VMI
ID: RFP_75A50324R00004Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR/ORM-SNSAtlanta, GA, 30341, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

CHEMICAL AND PHARMACEUTICAL PRODUCTS MANUFACTURING MACHINERY (3650)
Timeline
  1. 1
    Posted Sep 13, 2024, 12:00 AM UTC
  2. 2
    Updated Oct 2, 2024, 12:00 AM UTC
  3. 3
    Due Oct 7, 2024, 4:00 PM UTC
Description

The Department of Health and Human Services (HHS) is seeking proposals for the procurement of Pegfilgrastim 6MG/.06ML injection solutions and Vendor Managed Inventory (VMI) services under Solicitation No. 75A50324R00004. The primary objective is to ensure the availability of this critical medication, which is essential for treating acute radiation syndrome and supporting public health emergencies, through a five-year contract that includes a base year and four optional ordering periods. Interested contractors must adhere to strict compliance with FDA regulations, manage inventory effectively, and ensure rapid deployment capabilities during emergencies. Proposals are due by October 2, 2024, and inquiries can be directed to LaMonica Norwood at OSContracting@hhs.gov.

Point(s) of Contact
LaMonica Norwood
OSContracting@hhs.gov
Files
Title
Posted
The Technical - Past Performance Questionnaire is a component of a federal RFP requiring Offerors to submit past performance data for up to three contracts completed within the last three years. These contracts must be relevant in terms of scope, magnitude, and complexity in relation to the current RFP. For each contract, Offerors must provide basic information such as the contract number, agency name, and title, along with a narrative describing the work performed, relevant outcomes, challenges encountered, and corrective actions taken. Additionally, Offerors must disclose the contract's dollar value, type, performance period, and delivered products. A point of contact (POC) for each project must be provided to facilitate potential follow-up by the government for further clarification or evaluation. This request emphasizes the importance of past experience in securing new contracts, ensuring that Offerors demonstrate their capacity to fulfill the requirements set forth in the RFP based on previous successful engagements.
The HHS Industry User Guide for Subcontracting Plan Reviews outlines the procedures for vendors to submit subcontracting plans for evaluation by the Department of Health and Human Services (HHS). Vendors can access their plans through the SBCX account portal, where they will find sections for project summaries, subcontracting goals, document uploads, and communication with contracting officials. To complete a subcontracting plan, vendors must identify the plan type, report eligible subcontracting dollars, provide necessary goal data, and specify the Subcontracting Program Administrator. Additionally, they are required to describe inclusion efforts for small businesses and certify the plan's completion and compliance. After submission, a PDF version of the plan is available, and contracting officers may request revisions if needed. The evaluation process involves three approvers—Contracting Officer, Small Business Specialist, and SBA Procurement Center Representative. Support for technical issues is offered via email. This guide is essential for ensuring that vendors meet subcontracting goals while adhering to federal regulations in the context of RFPs and grants.
Oct 3, 2024, 4:37 AM UTC
This government request for proposal (RFP) outlines the U.S. Department of Health and Human Services' need for Pegfilgrastim 6MG/.06ML (inj, soln, syr, or autoinjector) and vendor-managed inventory (VMI) services, designed to support national preparedness against public health emergencies. The procurement will take place over a five-year period, including a one-year base period and four optional ordering periods. The contract anticipates a combination of firm-fixed price and time-and-material services, with a projected initial quantity of 18,300 units, increasing in subsequent years based on public health needs. The contractor must ensure compliance with FDA regulations and maintain a secure, temperature-controlled environment for inventory. The contractor is tasked with managing inventory effectively through VMI practices, ensuring sufficient stock levels and quality control within defined timelines. Shipping and transportation services for the products must align with stringent federal guidelines, emphasizing the importance of rapid deployment potential in emergencies. Overall, this solicitation underscores the federal government's commitment to maintaining robust health security capabilities and optimizing supply chain efficiency for essential pharmaceuticals.
Oct 3, 2024, 4:37 AM UTC
Amendment 1 to RFP 75A50324R00004 serves to update the proposal submission guidelines for contractors in relation to pharmaceutical supplies under the ASPR/SNS program. Key changes include an extension of the proposal submission deadline, now due by October 2, 2024, at 4:00 PM Eastern Time. The amendment also addresses questions and answers relevant to the RFP and provides a link for offerors to submit subcontracting plans. Additionally, it incorporates the FAR Clause 52.232-18 regarding the availability of funds for all Contract Line Item Numbers (CLINs) specified in the solicitation. The document outlines important codes, solicitation numbers, and identifies HHS as the administering entity, emphasizing adherence to Federal Acquisition Regulation (FAR) standards and procedures for offerors. Overall, the amendment ensures clarity in the procurement process and compliance with federal guidelines, facilitating a smoother submission and evaluation process for potential contractors.
Oct 3, 2024, 4:37 AM UTC
The document outlines a Request for Proposal (RFP) #75A50324R00004 from the Department of Health and Human Services (HHS) for the procurement of Pegfilgrastim 6MG/.06ML injection solutions and Vendor Managed Inventory (VMI) services. The RFP emphasizes a full and open competitive process and is not set aside for small businesses. It details that the HHS aims to secure this medication essential for treating acute radiation syndrome and supporting public health emergencies. Key components include an itemized breakdown of costs over a five-year period, including a base year and four optional ordering periods. The contractor is responsible for inventory management, quality control, transportation services, and ensuring compliance with cGMP and applicable FDA regulations. The scope requires maintaining optimal inventory levels, efficient storage, and disaster readiness with a focus on rapid deployment during emergencies. The contractor must adhere to strict protocols for shipping, labeling, and documenting inventory to guarantee timely access to the pharmaceuticals. Overall, this RFP highlights the government's proactive approach to public health preparedness by ensuring the availability of critical treatment options and enhancing logistical capabilities through VMI services.
The document outlines the Offeror Representations and Certifications for Commercial Products and Services, specifically focusing on the necessary certifications and compliance related to federal contracting. It requires Offerors to either confirm their annual certifications in the System for Award Management (SAM) or provide detailed representations concerning their business status, such as small business and veteran-owned classifications. Key definitions include small disadvantaged businesses, economically disadvantaged women-owned small businesses, and service-disabled veteran-owned small businesses, among others. The provision mandates disclosures regarding business operations, particularly concerning controversial areas like child labor, restricted operations in Sudan, and non-compliance with telecommunications regulations. It also includes stipulations about the "Buy American" requirements and certifications related to federal tax compliance and criminal convictions. The primary purpose of this document is to establish a baseline of representations and certifications necessary for Offerors participating in federal contracts, ensuring transparency and compliance with federal regulations, while also promoting socioeconomic goals within government procurement processes. It serves as a framework to verify the eligibility of contractors based on various criteria pertinent to federal funding, ensuring that the government contracts with responsible and qualified entities.
Oct 3, 2024, 4:37 AM UTC
The document pertains to a Request for Proposal (RFP) for acquiring Pegfilgrastim 6MG/.06ML (injection solution, syringe, or autoinjector) alongside Vendor Managed Inventory (VMI) services, identified as Solicitation No. 75A50324R00004. It includes a Q&A format addressing various contractor inquiries. The government intends to exercise option years unilaterally as specified in the solicitation. An extension for proposal submission has been granted until October 2, 2024. Questions raised include the possibility of extending the proposal deadline, checking the Strategic National Stockpile (SNS) coverage, and the evaluation criteria for domestic supply chains or ease of use in autoinjector forms. The government clarifies that all proposals will be reviewed without prioritizing domestic supply chains or autoinjector ease of use in evaluation criteria. Multiple pricing submissions for different Pegfilgrastim forms are allowed. The document's structure facilitates clear communication of responses to contractors while detailing expectations for proposal submissions in line with federal regulations and requirements.
Oct 3, 2024, 4:37 AM UTC
This document serves as a Solicitation Q&A Sheet for a government Request for Proposals (RFP). It is designed for contractors to submit questions concerning the RFP, with a structured format to capture pertinent details such as the section, page, and specific questions raised by the vendors. Each contractor's inquiry is followed by a government response that is highlighted in blue for clarity. The file contains multiple sections where questions and responses can be filled in, indicating ongoing interactions between the government and vendors regarding the RFP process. The purpose of this document is to ensure transparency and facilitate clear communication between the government and potential contractors, thereby enhancing the overall efficiency and effectiveness of the procurement process. By consolidating all questions and providing unified responses, the government aims to create an equitable environment for all vendors involved. Overall, this Q&A Sheet plays a crucial role in ensuring that all parties have a clear understanding of the RFP stipulations and expectations.
The document serves as a Solicitation Q&A Sheet related to RFP No. 75A50324R00004, outlining contractor inquiries and government responses concerning inventory management for a government contract. Key topics include inventory system access, production capacity requirements, deployment timelines for drug products in emergencies, and shelf-life criteria for deliveries. The government clarifies that contractors need not provide immediate complete inventory but must develop a detailed delivery schedule and production ramp-up strategy. Additionally, there is a twelve-hour notification for emergency shipment delivery, requiring contractors to maintain sufficient stock levels in compliance with regulations. The requirement for 90% shelf-life of products upon government procurement is also emphasized. Contractors must acknowledge amendments to the RFP and provide appropriate delivery timelines in case of increased quantities. Overall, the document highlights essential operational expectations for contractors to ensure effective supply management in public health emergencies.
This document outlines a pricing template for the procurement of Pegfilgrastim and related services through a federal government solicitation. The contract spans a base year from September 30, 2024, to September 29, 2025, with options for additional quantities and services extending through September 2029. Key components include the delivery of Pegfilgrastim injection solutions, vendor-managed inventory (VMI) services, and transportation services, all categorized under various Contract Line Item Numbers (CLINs). Each CLIN specifies quantity, pricing structure (firm fixed price or time and materials), and references a Statement of Work (SOW). The document delineates base quantities starting with 18,300 units, with potential increases in subsequent optional periods, reaching up to 60,300 units. The purpose of the RFP is to secure essential pharmaceutical supplies and services, illustrating the federal commitment to managing healthcare resources efficiently. This structured approach ensures clear financial expectations while adhering to procurement standards necessary for government contracts.
Lifecycle
Title
Type
Pegfilgrastim with VMI
Currently viewing
Combined Synopsis/Solicitation
Similar Opportunities
6505--Hydroxychloroquine SO4 Tablets
Buyer not available
The Department of Veterans Affairs is soliciting offers for the procurement of Hydroxychloroquine SO4 Tablets, specifically 200mg tablets, through its National Acquisition Center. The solicitation outlines the requirements for supply contracts, including compliance with Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), as well as the need for a unique National Drug Code (NDC) for each product. This procurement is crucial for ensuring a consistent supply of pharmaceuticals to government healthcare facilities, thereby maintaining availability and pricing stability. Interested contractors should note that the deadline for submitting offers has been extended to April 8, 2025, at 2:30 PM CDT, and can reach out to Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further inquiries.
Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking proposals for a contract titled "Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)." The primary objective of this procurement is to gain immediate and unlimited access to commercially available drug utilization data for both adult and pediatric populations in hospitals, which will support the FDA's regulatory activities related to drug safety and utilization assessments. This data is crucial for enhancing public health safety and informing regulatory decision-making regarding marketed drugs. Interested parties should note that the contract may cover up to $5 million over several years, with a response deadline of April 16, 2025. For further inquiries, potential offerors can contact Ryan Alexander at ryan.alexander@fda.hhs.gov.
6509--Solifenacin Tabletes (VA-25-00037090)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Solifenacin Tablets, aimed at ensuring a reliable supply for the VA, Department of Defense (DoD), and other federal health agencies. This unrestricted procurement will award one contract with a term of one year plus four optional renewal periods, requiring offerors to provide specific labeling, packaging details, and compliance with the Drug Supply Chain Security Act. The estimated annual requirements include various packaging sizes and quantities of Solifenacin, reflecting the VA's commitment to maintaining a consistent supply of essential medications for veterans and associated healthcare providers. Interested vendors should monitor SAM.gov for the solicitation release on or around March 14, 2025, with a response deadline of March 28, 2025; inquiries can be directed to Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
6505--Perphenazine Tablets (VA-25-00037353)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Perphenazine tablets under solicitation number VA-25-00037353. This contract aims to supply specified quantities of the drug to both the VA and the Department of Defense (DoD) through their Pharmaceutical Prime Vendor (PPV) Programs, with a focus on service-disabled veteran-owned small businesses, women-owned small businesses, and HUBZone small businesses. The procurement is critical for ensuring a consistent supply of pharmaceutical products while adhering to regulatory requirements, including the Drug Supply Chain Security Act (DSCSA) and FDA Good Manufacturing Practices (cGMP). Interested offerors must contact Contract Specialist Anthony DiCrescenzo at Anthony.DiCrescenzo@va.gov for further details, and proposals must include a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product.
Purchase of Lab Supplies
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified vendors to provide various lab supplies, including cleaning and sanitation products, under solicitation number 75N98025Q00021. The procurement aims to ensure the NIH is equipped with essential supplies such as paper towels, disinfectant wipes, and hand soap, which are critical for maintaining hygiene and safety in healthcare environments. This opportunity includes a partial small business set-aside, encouraging participation from small businesses, including service-disabled veteran-owned and women-owned enterprises, with a focus on timely delivery within a 10-day timeframe. Interested vendors must submit their quotes via email by 4:30 PM Eastern Daylight Time on April 9, 2025, and can direct inquiries to Carol Hayden at haydenc@od.nih.gov.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
6505--Loperamide Capsules (VA-25-00032225)
Buyer not available
The Department of Veterans Affairs (VA) is issuing a presolicitation notice for the procurement of Loperamide HCL 2MG Capsules under Request for Proposal (RFP) 36E79725R0025. This procurement aims to ensure a consistent supply of the medication not only for the VA but also for the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), with the intention to award one contract that spans one year with four optional one-year extensions. The estimated requirements include 18,690 bottles of 100 capsules and 47,289 bottles of 500 capsules annually, reflecting the importance of maintaining a steady supply of essential medications for healthcare facilities. Interested parties should note that the solicitation is expected to be electronically issued by April 17, 2025, with responses due by May 1, 2025; inquiries can be directed to Contracting Officer Andrew Cazares at Andrew.Cazares@va.gov or (719) 786-4990.
Dosimeters
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking contractors to provide dosimetry services for occupational radiation monitoring, including the supply of Optically Stimulated Luminescence (OSL) and Thermoluminescent Dosimeters (TLD). The primary objective is to ensure that radiation exposure for employees across various FDA offices and laboratories remains within the limits set by the Nuclear Regulatory Commission and the Occupational Safety and Health Administration. This procurement is critical for maintaining safety standards and monitoring radiation exposure effectively, supporting a workforce of up to 2,000 employees across multiple locations. Interested vendors must submit their quotes by April 7, 2025, and can contact Elena Tatarov at elena.tatarov@fda.hhs.gov for further details regarding the solicitation number FDA-25-1285024.
PRIMO Software Licensing
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
iNDI ALFAtag cell lines for the iPSC Neurodegenetive Disease Initiative (iNDI) project
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of iNDI ALFAtag cell lines as part of the iPSC Neurodegenerative Disease Initiative (iNDI) project. The objective is to generate up to 230 isogenic iPSC cell lines, including fluorescent ALFAtags for visualization, adhering to established quality control standards for research on Alzheimer's disease and related dementias. This initiative is crucial for advancing scientific understanding of neurodegenerative diseases and creating a publicly accessible cell repository. Interested vendors must submit their proposals by April 15, 2025, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@nih.gov, referencing solicitation number 75N95025Q00078.